Strong Endorsement and Market Expansion Potential Justify Buy Rating for Insmed's Brensocatib
Analysts Conflicted on These Healthcare Names: Insmed (INSM), Oric Pharmaceuticals (ORIC) and CytomX Therapeutics (CTMX)
Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and Zimmer Biomet Holdings (ZBH)
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Insmed (INSM)
Buy Rating Affirmed for Insmed on Positive Pipeline Prospects and Robust Revenue Forecasts
Insmed Analyst Ratings
Insmed Analyst Ratings
Buy Rating Affirmed for Insmed on Strong Sales and Promising Trial Outlook
Barclays Sticks to Its Buy Rating for Insmed (INSM)
Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and BioMarin Pharmaceutical (BMRN)
Analysts' Opinions Are Mixed on These Healthcare Stocks: American Well (AMWL), Biogen (BIIB) and Insmed (INSM)
Insmed Analyst Ratings
Buy Rating Affirmed for Insmed Amid Competitor Setbacks and Promising Market Expansion Opportunities
AN2 Therapeutics Extends Losses as Leerink Cuts on Trial Setback
Optimistic Outlook for Insmed's Brensocatib Program: Reaffirming Buy Rating Ahead of ASPEN Trial Results
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Insmed (INSM) and Amgen (AMGN)
Insmed's Strong Q4 Performance and Promising Outlook Justify Buy Rating
TD Cowen Sticks to Their Buy Rating for Insmed (INSM)
Analysts Are Bullish on These Healthcare Stocks: Insmed (INSM), Agilon Health (AGL)
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and Insmed (INSM)
No Data